SPDR S&P Biotech ETF
743 hedge funds and large institutions have $8.2B invested in SPDR S&P Biotech ETF in 2022 Q4 according to their latest regulatory filings, with 122 funds opening new positions, 231 increasing their positions, 240 reducing their positions, and 63 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more call options, than puts
Call options by funds: $ | Put options by funds: $
more funds holding
Funds holding: →
0.1% more ownership
Funds ownership: 94.67% → 94.78% (+0.1%)
4% less repeat investments, than reductions
Existing positions increased: 231 | Existing positions reduced: 240
6% less funds holding in top 10
Funds holding in top 10: 33 → 31 (-2)
Holders
743
Holding in Top 10
31
Calls
$1.66B
Puts
$1.31B
Top Buyers
| 1 | +$264M | |
| 2 | +$213M | |
| 3 | +$196M | |
| 4 |
APF
Alaska Permanent Fund
Juneau,
Alaska
|
+$151M |
| 5 |
MIFH
Migdal Insurance & Financial Holdings
Petach Tikva,
Israel
|
+$91.3M |
Top Sellers
| 1 | -$132M | |
| 2 | -$117M | |
| 3 | -$114M | |
| 4 |
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
|
-$113M |
| 5 |
Morgan Stanley
New York
|
-$109M |